Ch.1 Standard advertising | JPMA Guide Commentary | Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence

The "general advertisement," placed at the head of Part II, is the form of journal (print) advertising that allows you to say the most. Beyond the product name and a catchphrase, it can carry the indication, the dosage and administration, and the advertising product information (DI)—data and all. But breadth of expression is also breadth of room to mislead. So this chapter, which reads on its surface as a list of permissions for what you may include, is better read as a set of rules about where to stop precisely because so much is permitted.

This page explains the intent of Part II, Chapter 1 (General Advertisements) of the "Guidelines for the Preparation of Product Information Summaries for Prescription Drugs," tied to the spirit of the foreword and to the logic of statistics and evidence. It reconstructs the meaning in its own words rather than reproducing the original text. For actual preparation, always consult the current edition and the package insert (electronic).

01What a general advertisement is—the place of the "ad that can speak"

Journal advertisements split into three kinds by what they carry: the name-only advertisement that stays with the product name, the editorial-style advertisement built like an article, and this general advertisement. The general advertisement comes with advertising DI and may carry features, data, and a catchphrase. Among the three types it has the widest expressive latitude.

Yet latitude is, by the spirit of the foreword, a property to watch. The foreword positions the package insert as the basis of proper-use information, with the product information summary and other materials serving to "supplement" it. Advertising is no exception. The original is the approved content; the advertisement cannot exceed the scope of approval by a single character. More to say does not widen what may be said—and the more there is to say, the easier it becomes to spill past the approved scope.

Why mandatory items are imposed on the general advertisement

The general advertisement has items that must appear. The name, comprising both brand and generic names; the therapeutic classification name; the regulatory category; the indication (with its related cautions); the dosage and administration (likewise with related cautions); the precautionary information including warnings and contraindications; whether the drug is listed in the drug tariff; the marketing authorization holder's name (with the contact for literature requests and inquiries); where applicable, notes on insurance benefits and approval conditions; and the date of preparation. These are not "include them if you can" items—they are the skeleton without which the advertisement does not stand as one.

The reason mandatory items exist lies in the foreword's twofold duty: to convey accurately and not to mislead. An advertisement that speaks loudly of effect while omitting who may use it and what dangers it carries leaves a false picture even when it tells no lie. Mandatory items embed, on the advertising side and as an obligation set in advance, the minimum set of information a reader needs to reach a safe prescribing judgment.

Item	Treatment in a general ad	Underlying rationale
Name	Both brand and generic	Leave no ambiguity in identifying the product
Indication / dosage	Stated with related cautions	Mirror the scope of approval accurately
Warnings / contraindications	Mandatory as precautionary information	Never drop the most critical safety information
Tariff listing / MAH name	Listing status and inquiry contact	Secure the distribution and inquiry routes
Date of preparation	Always stated	Preserve the version for later verification

02The discipline of type size—how it looks is part of the information

Body text in a general advertisement is set at 6 points or larger. Warnings and contraindications go further: gothic (bold) type, 8 points or larger, set to stand out. Pinning the lower bound to a number looks like over-fine regulation, but a clear idea sits behind it.

Information changes meaning not only by whether it appears but by how it appears. Raise the effect in a large headline and bury the contraindication in a footnote too small to read, and though both are formally present, only the effect stays in the reader's mind. This is the classic "true but misleading." Once the foreword set "do not mislead" as a duty independent of, and alongside, the prohibition on falsehood, the discipline of appearance becomes its very implementation. Specifying a minimum size and even a typeface for warnings and contraindications is a structural defense against the heaviest safety information vanishing from view.

Type size is not a matter of "legible is enough." A layout that shows efficacy relatively large and sinks safety small itself invites underestimation of safety. Think of the size floor as a way to block that manipulation of relative emphasis.

03What must not appear—reference information, competitor comparisons, case reports

The general advertisement names things that clearly must not appear. First, "reference information." Second, comparative trials against other companies' products. Third, case presentations. Each can be handled under defined conditions in deeper, broader materials (the product information summary or presentation content), but not in the limited space of an advertisement. Why the advertisement alone is stricter follows from the nature of each.

Why reference information is excluded

Reference information means results obtained secondarily within the approved scope—quality of life, daily activity, pharmacological actions whose link to the indication is unclear. In a product information summary these may be carried if labeled and segregated as "reference information," but an advertisement carries none of it. An advertisement is received quickly, and a segregation label works poorly there. If information that is not the core of approval appears seamlessly next to the indication, it leads readers to misperceive the scope of approval. So the advertisement does not bring it in at all.

Why competitor-comparison trials are excluded

Put a comparative trial against another company's product into an advertisement, and the medium's nature makes the temptation to excerpt only the winning part nearly unavoidable. One of the design pillars the foreword supports is the ban on disparagement and on selective, contrived extraction. In an advertisement that cannot fully supply the comparison's context, raising a head-to-head comparison drifts toward making the rival look unfairly low. The line—an advertisement simply does not take up this subject—prevents the accident in advance.

Why case presentations are excluded

A case presentation always carries the danger that one vivid course shapes the picture of the whole drug. Generalizing the impression of a few cases runs head-on against the idea of the evidence hierarchy. A case report sits low in that hierarchy, and speaking of effect from a single case has no scientific support. The advertisement is the medium where this impression-shaping force works most easily, so case presentations are kept out.

The three exclusions are not scattered prohibitions but expressions of one principle. An advertisement is received fast and resists added context, so information that misleads without context is kept out from the start. This resonates with the foreword's implication that "not exhaustive does not mean free."

04The ban on exaggeration and guarantees—why "few side effects" cannot be written

A general advertisement must make no superlative claims, no guarantees, and no safety emphasis such as "few side effects." This is not a question of taste but a prohibition rooted in the logic of statistics and approval.

The flat assertion "few side effects" leaves only reassurance, without ever showing few compared to what. Even if a comparative trial showed a difference, statistical significance does not by itself mean clinical significance. Conversely, the absence of a significant difference does not prove "equivalence." A safety claim properly stands only when it carries these subtle distinctions—yet the single word "few" skips all of them. So categorical safety emphasis is not allowed.

Superlatives and guarantees follow the same reasoning. "Most effective" or "certain to work" become assertions beyond what evidence can show. What a clinical trial can speak of is an effect observed at some probability under certain conditions—not the absolute or the supreme. When an advertisement crosses that boundary, it brings a promise science cannot support into the clinical setting.

Safety information carries an asymmetric duty unlike efficacy. The rule is to disclose even unfavorable information, and processing it to look favorable is not allowed. The ban on "few side effects" drops this asymmetry into the wording of the advertisement itself.

05How to build the page—portraits, catchphrases, regulatory display

The general advertisement sets several concrete brakes on the very construction of the page. As fifth-level detail, it is worth expanding these carefully.

Do not make portrait photos the main element

Do not build an advertisement around portrait photographs of people. Introducing the participants of a roundtable is an exception, but otherwise putting the photo of a celebrity or physician front and center is not permitted. The persuasive force of a photo creates the impression that "an authority recommends this," independent of what the data contain. This stages trust through appearance rather than the quality of information, against the duty not to mislead.

Do not repurpose the therapeutic classification name as a catchphrase

Detaching the therapeutic classification name from the product name and using it like a catchphrase is not permitted. The classification name is information that locates the product objectively; it is not a striking slogan to set walking on its own. Held up large and apart from the product name, it breeds the misperception that the classification is some intrinsic merit of the product.

Display for prescription drugs

For prescription drugs, state the regulatory category "prescription drug" explicitly, and alongside it the note "Caution—use only under the prescription of a physician or the like." This display fixes the entry to distribution and use at the physician's judgment, ruling out any impression that anyone may use it.

Full indications in specialty-field advertisements

Even an advertisement aimed at a specific specialty field must not stop at that field's indication alone. In addition to the indication for that field, state the full text of the other approved indications as well. Showing only a convenient slice to specialists would either misperceive the approved scope as narrower than it is, or unduly emphasize a particular use. Not omitting the whole picture of approval is the honesty required here.

Page issue	Principle	Exception / note
Portrait photos	Not the main element	Introducing roundtable participants is allowed
Therapeutic classification name	No catchphrase repurposing	Show accurately, unified with the product name
Prescription drugs	State category and use caution	—
Specialty-field ads	State other approved indications in full	Do not stop at the field's indication

06Rereading the general advertisement through the foreword's spirit

The rules so far look like separate prohibitions, yet they converge on the few pillars the foreword raised. Do not exceed the scope of approval (state indication and dosage accurately, with related cautions, and the full indications even in a specialty field). Do not mislead (the size floor, the limit on portraits, the discipline over catchphrases). Disclose safety information even when unfavorable (mandatory warnings and contraindications with their size, and the ban on safety emphasis). And do not bring context-dependent information into a medium that resists adding context (the exclusion of reference information, competitor comparisons, and case presentations).

The general advertisement can say the most among the three types. For that very reason, it is the form that must most consciously keep apart what it can say from what it may say. Permitted freedom holds only in a set with the line at which to stop.

In closing

The general advertisement has the widest expressive range among journal advertisements, and with it the most paths to misperception. The mandatory items, the type size, the three exclusions (reference information / competitor comparison / case presentation), the ban on exaggeration and guarantees, and the brakes on page construction are all devices that fix where to stop precisely because so much may be included.

At the root lies the spirit of the foreword—do not exceed the scope of approval, do not mislead even with facts, disclose safety information even when unfavorable. To make a general advertisement well is nothing other than satisfying these three at once on a limited page.

Case studies — the "it isn't written, so…" mindset, and how each lands

Regular advertisements carry the broadest expressive latitude of the three format types — and the wider the latitude, the more paths there are to mislead. The four scenarios below trace how someone might try to use the literal wording of the provisions as a shield against their intent, and where each approach lands.

GRAY 1 — Straying from the spirit (untouched by the wording, but against the foreword's spirit)

The scheme: "The rules say warnings and contraindications must be in Gothic type at 8 pt or above — so I'll hit 8 pt exactly and push the block to the very bottom of the page. Meanwhile, I'll run the efficacy headline at 36 pt across the top. The numbers all check out."

Verdict: GRAY 1. The 8 pt floor is met in the strict numerical sense, so no single provision is broken. But the intent behind the type-size rules is that safety information must be visually balanced against efficacy claims — not technically present while functionally invisible. A 36 pt efficacy header paired with 8 pt contraindication text creates exactly the kind of relative suppression the rule was designed to prevent. Regulators assess "misleading by design," not just whether each box is ticked. The correct approach is to size warnings at a level that keeps them genuinely legible in proportion to surrounding content.

GRAY 2 — Exploiting the gap (deliberately working a loophole to invite misreading)

The scheme: "The rules ban 'supplementary information' from regular ads, but the rules only ban that specific label. If I call the same QOL scores and patient-satisfaction figures 'supporting data' or 'related evidence,' the prohibition has no name to attach to them."

Verdict: GRAY 2. The label matters far less than the nature of what is being shown. The reason supplementary information is excluded from regular ads is that data without a direct link to the approved indication tends to be read as part of the approved efficacy picture when there is no space to explain the distinction. Renaming the box does not change what the reader infers. Placing QOL data alongside an efficacy table in a format that offers no room for context is the precise harm the rule targets. The name-swap is a classic gap exploit and is likely to be treated as such under the Fair Advertising Standards and the JPMA Code.

GRAY 3 — Violating higher norms (arguably "not in the text," yet almost certainly out under the PMD Act, Fair Advertising Standards, and the JPMA Code)

The scheme: "Saying 'fewer side effects' outright is banned. But 'showed a tendency toward fewer side effects' is not an assertion — it is a hedge. No comparison group, no p-value, just a softened impression that does the same job."

Verdict: GRAY 3. Softening the verb does not soften the safety claim. No comparator is named, no statistical basis is given, and the reader is left with the impression that the drug is safer than alternatives — which is precisely what the prohibition on safety superiority claims is designed to prevent. The Fair Advertising Standards ban on exaggerating safety covers the impression created, not just the grammatical form. Article 66 of the PMD Act on misleading advertising reaches the same conclusion. Regulators look at what the reader takes away, not at what the author technically asserted.

BLACK — Breaching the explicit text (a plain violation of the provision itself)

The scheme: "Space is tight, so I'll set the warnings and contraindications at 4 pt. They are technically on the page, so the disclosure requirement is met. Whether anyone can actually read them is a separate question."

Verdict: BLACK. The 6 pt floor for body text and the 8 pt floor for warnings and contraindications are absolute minimums, not targets to approach from below. Setting type at 4 pt is a numerical violation of the explicit provision, regardless of whether the text is physically present on the page. Space constraints are not a valid excuse — if the layout cannot accommodate the required sizes, the layout must be redesigned. This class of violation is subject to administrative action under the PMD Act.

Improper intent by implication — three scopes of "insinuating" without stating it

Regular advertisements carry the widest vocabulary of any ad format. That breadth means a single word, the pairing of adjacent clauses, or a tilted page layout can silently convey impressions that exceed the approved indication. None of the three examples below violates explicit text — all three are nonetheless grey-zone findings.

Implication 1 — Local: carried in a single word or sentence

How it is built: "A tagline reading 'Breathe again.' is printed in large type at the top of the ad. The pharmacological category is correctly stated as 'bronchodilator'; no unapproved indication is named."

Intent that can be read: The verb phrase 'breathe again,' placed beside the category name 'bronchodilator,' prompts readers to imagine a broader range of conditions (severe asthma, interstitial lung disease, etc.) than the approved indication covers.

Verdict: A single phrase, through contextual association, implies efficacy beyond approval. Taglines must not only avoid contradicting the approved indication; they must not generate expectations beyond it. 'Breathe again' can suggest remission of conditions outside the approved scope. The correct approach is to draft taglines with awareness of adjacency to the pharmacological category label, staying within the boundaries of the approved indication.

Implication 2 — Adjacent: read across neighboring clauses

How it is built: "The mandatory field 'selective β₂-agonist' is followed on the very next line by an optional sub-tagline: 'A new possibility for moderate-to-severe management.' The pharmacological category is accurate; the word 'possibility' qualifies the claim."

Intent that can be read: Readers borrow the authority of the mandatory field to anchor the adjacent phrase 'moderate-to-severe,' reading it as part of the approved scope. The hedge word 'possibility' does not neutralize the impression.

Verdict: Adjacency creates a meaning bridge. When a mandatory item and a promotional phrase appear consecutively, readers process them as a unit. If 'moderate-to-severe management' falls outside the approved indication, the juxtaposition itself becomes the source of misunderstanding. Mandatory fields and promotional copy must be separated by a clear visual and spatial break.

Implication 3 — Whole-context: arising from the document as a whole

How it is built: "Roughly 70% of the page area is devoted to efficacy data (three bar charts for primary endpoints, two line graphs for secondary endpoints). Warnings and contraindications are confined to seven lines at the bottom of the final page, in the required typeface and size, with no omissions."

Intent that can be read: The heavy tilt toward efficacy creates an impression of 'highly effective, few risks' before the reader reaches the safety section. The warnings are present and complete but effectively invisible.

Verdict: Page layout itself can compromise the practical visibility of safety information. The Guidelines' principle is 'no falsehood, and no misunderstanding'; they evaluate not only whether information is present but whether it can actually be read. Extreme imbalance between the space devoted to efficacy and to safety constitutes a misleading document structure, even when every mandatory item is technically included.